Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms

被引:16
|
作者
Barzilai, Merav [1 ,2 ]
Kirgner, Ilya [1 ,2 ]
Avivi, Irit [1 ,2 ]
Ellis, Martin [2 ,3 ]
Dally, Najib [4 ,5 ]
Rozovski, Uri [2 ,6 ]
Lavi, Noa [5 ,7 ]
机构
[1] Sourasky Med Ctr, Div Hematol, Weitzman 6, Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Meir Med Ctr, Div Hematol, Kefar Sava, Israel
[4] Ziv Med Ctr, Div Hematol, Safed, Israel
[5] Technion, Rappaport Fac Med, Haifa, Israel
[6] Rabin Med Ctr, Div Hematol, Petah Tiqwa, Israel
[7] Rambam Med Ctr, Div Hematol, Haifa, Israel
关键词
essential thrombocytosis; myelofibrosis; myeloproliferative neoplasm; polycythemia vera; young adults; ESSENTIAL THROMBOCYTHEMIA; PRIMARY MYELOFIBROSIS; RISK-STRATIFICATION; POLYCYTHEMIA-VERA; THROMBOSIS; SURVIVAL; DISEASE; TRANSFORMATION; ADOLESCENT; DIAGNOSIS;
D O I
10.1111/ejh.13232
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Approximately 10% of Philadelphia (Ph)-negative myeloproliferative neoplasms (NPM) are diagnosed at young adulthood. We aim to define the features of this group. Methods A multicenter retrospective study, including patients 18-45 years of age, diagnosed with Ph-negative MPN between 1985 and 2017. Results One hundred nine patients were included, 37 with polycythemia vera (34%), 54 with essential thrombocytosis (50%), 15 with primary myelofibrosis (PMF) (14%), and 3 with MPN unclassifiable (3%). Median age was 33 years and 62 (57%) were females. During a median follow-up of 8 years, 39 patients (37%) had at least one thrombotic event. 30/39 of events were venous (77%), 23/30 of which were splanchnic (77%). In 14/39 (36%), thrombosis preceded MPN diagnosis. In a multivariable analysis, only splenomegaly predicted for thrombosis (HR 5.6, CI: 1.4-22). The 10-year risk for secondary myelofibrosis was similar for ET and PV (0.13 vs 0.19, P = 0.51). The 10-year risk for leukemic transformation or mortality was significantly higher for PMF (0.3, P = 0.04). Conclusions The risks of mortality and of progression to MF/leukemia in young adults are similar to older population. Thrombotic events are frequently a presenting sign with a high incidence of venous, in particular splanchnic, events.
引用
收藏
页码:504 / 508
页数:5
相关论文
共 50 条
  • [1] Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications
    Sefer, D.
    Bizic-Radulovic, S.
    Kraguljac-Kurtovic, N.
    Bogdanovic, A.
    Cokic, V.
    Miljic, P.
    Beleslin-Cokic, B.
    Knezevic, V.
    Mitrovic-Ajtic, O.
    Lekovic, D.
    Gotic, M.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, 39 (01) : 21 - 31
  • [2] Serum procalcitonin in Philadelphia-negative myeloproliferative neoplasms
    Krecak, Ivan
    Peran, Nena
    Lapic, Ivana
    Gveric-Krecak, Velka
    Krecak, Filip
    Roncevic, Pavle
    Durakovic, Nadira
    WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (1-2) : 62 - 64
  • [3] Smoking and philadelphia-negative chronic myeloproliferative neoplasms
    Sorensen, Anders Lindholm
    Hasselbalch, Hans Carl
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (01) : 63 - 69
  • [4] Serum procalcitonin in Philadelphia-negative myeloproliferative neoplasms
    Ivan Krečak
    Nena Peran
    Ivana Lapić
    Velka Gverić-Krečak
    Filip Krečak
    Pavle Rončević
    Nadira Duraković
    Wiener klinische Wochenschrift, 2021, 133 : 62 - 64
  • [5] Inflammatory picture of Philadelphia-negative myeloproliferative neoplasms
    Barbosa Pagnano, Katia Borgia
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2018, 40 (02) : 101 - 102
  • [6] CLINICAL-MOLECULAR CHARACTERIZATION OF YOUNG ADULTS (<45 YEARS) WITH MYELOPROLIFERATIVE PHILADELPHIA-NEGATIVE NEOPLASMS
    Patricia, Velez
    Campos Marcio, Andrade
    Lierni, Fernandez-Ibarrondo
    Joan, Gibert
    Maria Concepcion, Fernandez
    Ramon, Diez-Feijoo
    Brayan, Merchan
    Nieves, Garcia-Gisbert
    Leonor, Arenillas
    Laura, Camacho
    Sara, Garcia-Avila
    Raquel, Longaron
    Antonio, Salar
    Carles, Besses
    Beatriz, Bellosillo
    HAEMATOLOGICA, 2021, 106 (10) : 122 - 122
  • [7] Molecular characterization of Philadelphia-negative myeloproliferative neoplasms
    Brisci, Angela
    Pietra, Daniela
    Foglieni, Barbara
    Boggi, Sabrina
    Rumi, Elisa
    Passamonti, Francesco
    Ferrari, Maurizio
    Cremonesi, Laura
    BIOCHIMICA CLINICA, 2010, 34 (02) : 110 - 114
  • [8] Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms
    Kennedy, James A.
    Atenafu, Eshetu G.
    Messner, Hans A.
    Craddock, Kenneth J.
    Brandwein, Joseph M.
    Lipton, Jeffrey H.
    Minden, Mark D.
    Schimmer, Aaron D.
    Schuh, Andre C.
    Yee, Karen W.
    Gupta, Vikas
    BLOOD, 2013, 121 (14) : 2725 - 2733
  • [9] Sepsis-Related Outcomes of Patients with Philadelphia-Negative Myeloproliferative Neoplasms
    Gonzalez-Mosquera, Luis F.
    Moscoso, Bernard
    Tobar, Pool
    Cardenas-Maldonado, Diana
    Podrumar, Alida I.
    Mesa, Ruben
    Cuenca, John A.
    CANCER INVESTIGATION, 2023, 41 (05) : 423 - 431
  • [10] Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms
    Boddu, Prajwal
    Masarova, Lucia
    Verstovsek, Srdan
    Strati, Paolo
    Kantarjian, Hagop
    Cortes, Jorge
    Estrov, Zeev
    Pierce, Sherry
    Pemmaraju, Naveen
    ANNALS OF HEMATOLOGY, 2018, 97 (01) : 109 - 121